Media & Resources

The St. Stephen’s Centre at the Chelsea and Westminster Hospital in London is preparing for the start of a new trial to test an HIV vaccine candidate.  The trial is anticipated to provide important information on the ability of the vaccine to stimulate an immune response that may be able to protect against HIV infection…

On Nov. 26, the Lancet published a paper by Reuben Granich et al exploring through a mathematical model the theoretical effect on the AIDS epidemic of an intensive program of HIV testing and treatment. The authors explored what might happen in a community if every individual above the age of 15 voluntarily received an HIV…

THE INTERNATIONAL AIDS VACCINE INITIATIVE OPENS STATE-OF-THE-ART LABORATORY IN PLANNED NEW BIOSCIENCE CENTER IN NEW YORK CITY NEW YORK, November 12, 2008 — Today New York City Mayor Michael R. Bloomberg honored the International AIDS Vaccine Initiative (IAVI) at a ribbon-cutting ceremony for its new AIDS Vaccine Design and Development Laboratory—a 36,000 square foot, state-of-the-art…

Washington, DC — Around the world, at the end of 2007, there were an estimated 33.2 million people living with HIV/AIDS. 2 million of those living with HIV/AIDS were children, and 2.5 million were newly infected. More than 2 million people died of HIV/AIDS worldwide in 2007. Every day during that year 1,000 children became…

LONDON, 4 November 2008—The International AIDS Vaccine Initiative (IAVI) applauds the UK government for strengthening its support for research into new prevention technologies to fight HIV/AIDS. During a meeting of scientists and experts convened by the UK Department for International Development, International Development Minister Gareth Thomas announced that the UK government would contribute £220 million…

IAVI Ranks among Top One Percent of Charities Nationwide NEW YORK, October 29, 2008 – For the seventh consecutive year, the International AIDS Vaccine Initiative (IAVI) has received a four-star rating from Charity Navigator, America’s largest independent evaluator of charities.  This rating indicates that IAVI, the world’s only nonprofit organization dedicated solely to AIDS vaccine…

IAVI awards innovation grant to South African biotech company for the development and testing of new vaccine antigens that elicit broadly neutralizing antibodies against HIV JOHANNESBURG, October 10, 2008 – Elevation Biotech, a start-up biotechnology company funded by LIFElab, an agency of the South African Department of Science and Technology, and the International AIDS Vaccine…

Goal is to solve the number one scientific problem impeding AIDS vaccine development LA JOLLA, CA, and NEW YORK, NY, September 30, 2008 — The Scripps Research Institute, one of the world’s largest independent, non-profit biomedical research organizations, and the International AIDS Vaccine Initiative (IAVI), the world’s only global non-profit organization focused solely on AIDS…